Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Baraté C, Pane F, Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C, Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M, Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M, Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M, Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G, Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A, Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A. Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice. haematol [Internet]. 2020Sep.10 [cited 2025Dec.22];. Available from: https://haematologica.org/article/view/12141